StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15+0.01 (+4.07%)

Close on Nov 17, 2026Market cap $10.23MP/E –Yield –

TScan Therapeutics total assets

Total assets on the balance sheet at the end of each period.

TScan Therapeutics's total assets was $171.45M at Jun 30, 2026. For fiscal 2025 it was $228.79M, down 38.4% from the year before. The highest annual figure on record is $371.12M in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$228.79M-38.4%
FY2024Dec 31, 2024$371.12M+36.4%
FY2023Dec 31, 2023$272.15M+36.7%
FY2022Dec 31, 2022$199.09M+5.8%
FY2021Dec 31, 2021$188.11M+278.2%
FY2020Dec 31, 2020$49.74M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$171.45M-42.6%
Q1 FY2026Mar 31, 2026$201.99M-39.3%
Q4 FY2025Dec 31, 2025$228.79M-38.4%
Q3 FY2025Sep 30, 2025$262.23M-24.7%
Q2 FY2025Jun 30, 2025$298.56M-20.4%
Q1 FY2025Mar 31, 2025$332.71M+38.1%
Q4 FY2024Dec 31, 2024$371.12M+36.4%
Q3 FY2024Sep 30, 2024$348.03M+19.4%
Q2 FY2024Jun 30, 2024$374.87M+18.3%
Q1 FY2024Mar 31, 2024$240.83M+38.7%
Q4 FY2023Dec 31, 2023$272.15M+36.7%
Q3 FY2023Sep 30, 2023$291.38M+76.1%
Q2 FY2023Jun 30, 2023$316.92M+107.9%
Q1 FY2023Mar 31, 2023$173.58M+3.2%
Q4 FY2022Dec 31, 2022$199.09M+5.8%
Q3 FY2022Sep 30, 2022$165.45M-19.2%
Q2 FY2022Jun 30, 2022$152.42M+17.2%
Q1 FY2022Mar 31, 2022$168.20M+238.2%
Q4 FY2021Dec 31, 2021$188.11M–
Q3 FY2021Sep 30, 2021$204.89M–
Q2 FY2021Jun 30, 2021$130.01M–
Q4 FY2020Dec 31, 2020$49.74M–

More TScan Therapeutics figures

See a number that looks wrong?